New cancer drug SHR-3821 enters first human tests
NCT ID NCT06618651
First seen Nov 17, 2025 · Last updated Jun 23, 2026 · Updated 34 times
Summary
This early-stage trial tests a new drug called SHR-3821 in 162 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see early signs of tumor shrinkage. Participants receive the drug by injection and are closely monitored for side effects and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan Hospital
RECRUITINGChengdu, Sichuan, 610000, China
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-3821 injection
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong
This is an early Phase 1 trial with only 162 participants, so the drug may not prove safe or effective. Side effects are unknown and could be serious.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.